140410.KQ
Mezzion Pharma Co.,Ltd.
KOE · Healthcare · Medical - Pharmaceuticals · KR
KRW 65,000.00
−1.66%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 8.4B | 7.9B | 8.6B | 31.7B | 30.7B |
| Cost of Revenue | 8.1B | 7.4B | 6.7B | 27.8B | 31.0B |
| Gross Profit | 312.3M | 464.2M | 1.9B | 3.9B | (313.4M) |
| Operating Expenses | |||||
| R&D Expense | 1.3B | 1.3B | 294.0M | 939.0M | 2.2B |
| SG&A Expense | 14.3B | 10.8B | 10.2B | 9.4B | 10.9B |
| General & Admin Expense | 5.8B | 5.0B | 4.4B | 4.5B | 5.1B |
| Selling & Marketing Expense | 4.0B | 5.8B | 5.8B | 4.9B | 5.8B |
| Other Expenses | 3.4B | 5.2B | 5.7B | 8.1B | 9.9B |
| Total Operating Expenses | 18.9B | 17.2B | 16.2B | 18.4B | 23.0B |
| Cost and Expenses | 27.2B | 24.7B | 22.9B | 46.2B | 54.1B |
| Operating Income (EBIT) | (13.9B) | (16.8B) | (14.3B) | (14.5B) | (23.3B) |
| Non-Operating | |||||
| Interest Income | 700.1M | 622.0M | 1.4B | 1.5B | 763.3M |
| Interest Expense | 3.2B | 1.6B | 300.8M | 164.8M | 423.4M |
| Net Interest Income | (2.5B) | (950.0M) | 1.1B | 1.3B | 339.9M |
| Other Non-Op Income/Expense | (15.4B) | (22.1B) | (234.3M) | 2.0B | (12.6B) |
| Non-Operating Income (excl Interest) | 20.6B | — | (66.5M) | (2.3B) | 12.2B |
| EBT (Pre-Tax Income) | (29.3B) | (38.8B) | (14.5B) | (12.5B) | (35.9B) |
| Income Tax Expense | (2.0B) | (3.9B) | 4.9B | 248.1M | 388.2M |
| Bottom Line | |||||
| Net Income | (27.4B) | (34.9B) | (19.5B) | (12.7B) | (36.3B) |
| Earnings from Cont. Ops | (27.4B) | (34.9B) | (19.5B) | (12.7B) | (36.3B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (27.4B) | (34.9B) | (19.5B) | (12.7B) | (36.3B) |
| Per Share | |||||
| Basic EPS | (₩904) | (₩1,150) | (₩655) | (₩451) | (₩1,358) |
| Diluted EPS | (₩909) | (₩1,150) | (₩655) | (₩451) | (₩1,358) |
| Revenue Per Share | ₩277 | ₩260 | ₩290 | ₩1,124 | ₩1,150 |
| Shares | |||||
| Basic Shares Outstanding | 30.4M | 30.4M | 29.7M | 28.2M | 26.7M |
| Diluted Shares Outstanding | 31.0M | 30.4M | 29.7M | 28.2M | 26.7M |
| Profitability Metrics | |||||
| EBITDA | (17.8B) | (15.8B) | (13.3B) | (10.6B) | (21.7B) |
| D&A | 882.9M | 988.1M | 957.8M | 1.5B | 1.7B |
| EBIT | (18.6B) | (16.8B) | (14.2B) | (12.2B) | (23.3B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026